Personal information

Activities

Collapse all

Works (8)

An Analysis of 20 Cases of Radiation-Associated Sarcoma, Including 4 Cases Treated by Carbon Ion Radiotherapy

Oncology
2022 | Journal article
DOI: 10.1159/000521504
Contributors: Takahito Negishi; Akira Matsunobu; Makoto Endo; Ryouhei Yokoyama; Shuhei Kusano; Nobuki Furubayashi; Kenichi Taguchi; Yoshiyuki Shioyama; Keiichiro Iida; Toshifumi Fujiwara et al.
Source: check_circle
Crossref

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status

OncoTargets and Therapy
2022-11 | Journal article
DOI: 10.2147/OTT.S389138
Contributors: Nobuki Furubayashi; Akinori Minato; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Mirii Harada; Shingo Tamura; Hiroki Kobayashi et al.
Source: check_circle
Crossref

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab

Cancer Management and Research
2022-05 | Journal article
DOI: 10.2147/CMAR.S360473
Contributors: Nobuki Furubayashi; Akinori Minato; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Mirii Harada; Shingo Tamura; Akihiro Miura et al.
Source: check_circle
Crossref

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab

Cancer Management and Research
2021-10 | Journal article
DOI: 10.2147/CMAR.S333823
Contributors: Nobuki Furubayashi; Akinori Minato; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Shingo Tamura; Kentaro Kuroiwa; Narihito Seki et al.
Source: check_circle
Crossref

Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney with Bone Metastases: The First Case Report

2021-04-06 | Other
DOI: 10.21203/rs.3.rs-386219/v1
Contributors: Nobuki Furubayashi; Takahito Negishi; Kenichi Taguchi; Akihiro Miura; Yoshiaki Sato; Motonobu Nakamura
Source: check_circle
Crossref

Organ-Specific Tumor Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-Based Chemotherapy

OncoTargets and Therapy
2021-03 | Journal article
DOI: 10.2147/OTT.S299724
Contributors: Nobuki Furubayashi; Takahito Negishi; Naotaka Sakamoto; Hozumi Shimokawa; Futoshi Morokuma; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Noriaki Tokuda; Narihito Seki et al.
Source: check_circle
Crossref

Optimal Timing of Sequencing From Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-World Data: A Multi-Institutional Retrospective Study

2020-12-03 | Other
DOI: 10.21203/rs.3.rs-116673/v1
Contributors: Nobuki Furubayashi; Futoshi Morokuma; Toshihisa Tomoda; Yoshifumi Hori; Takahito Negishi; Akihiro Miura; Nobutaka Nakamura; Yoshiaki Sato; Noriaki Tokuda; Kentaro Kuroiwa et al.
Source: check_circle
Crossref

<p>Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma</p>

Research and Reports in Urology
2020-10 | Journal article
DOI: 10.2147/RRU.S270495
Contributors: Nobuki Furubayashi; Takahito Negishi; Akihiro Miura; Nobutaka Nakamura; Motonobu Nakamura
Source: check_circle
Crossref
How many people are using ORCID?